GlaxoSmithKline News and Research

RSS

Roundup: Brown's pension plan no panacea for Calif.; Personhood amendment won't make Colo. ballot

Even by the most ambitious forecasts, the plan Gov. Jerry Brown and fellow Democrats are championing to contain government worker pensions in California could leave state taxpayers awash in debt to public employees.

31 Aug 2012

Six manufacturers receive FDA approval to produce 2012-2013 flu vaccines

The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.

14 Aug 2012

GSK begins shipping the first lots of 2012-2013 seasonal influenza vaccines

GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers.

1 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

When checks and balances in the pharmaceutical marketplace fall short

The Washington Post explores how a trio of very expensive anemia drugs became "superstars" in the marketplace. Also, The Wall Street Journal tracks the process by which certain fake cancer drugs found their way into the United States.

21 Jul 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

Longer looks: Keeping Parkinson's a secret

When Nancy Mulhearn learned she had Parkinson's disease seven years ago, she kept the diagnosis mostly to herself, hiding it from friends, colleagues -- even, at first, her mother, sister and teenage children. After seven months, she decided she had to tell her family, and they settled into an unspoken agreement not to talk about the disease.

13 Jul 2012

GlaxoSmithKline agrees to plead guilty, pay $3B settlement

Drugmaker GlaxoSmithKline has agreed to plead guilty to fraud charges and pay $3 billion in total -- with some money going to nearly every state -- for promoting its bestselling antidepressants such as Paxil and Wellbutrin for unapproved uses, failing to report safety data about a top diabetes drug and improperly marketing other drugs.

4 Jul 2012

First Edition: July 3, 2012

Today's headlines include reports that continue to delve into the policy-oriented and political repercussions of last week's high court decision on the health law.

3 Jul 2012

Success in fighting malaria helping to fuel Africa's economic growth, Reuters reports

Reuters examines how the fight against malaria in Africa is helping to fuel the continent's economic growth. "

22 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012

Supreme Court rules drug firms don't have to pay overtime to sales reps

The 5-4 opinion by Justice Samuel Alito says the sales representatives are not subject to the overtime pay provisions of the Fair Labor Standards Act.

20 Jun 2012

KineMed, GSK enter multi-year biomarker discovery partnership

KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc that will apply KineMed's proprietary biomarker discovery platform in therapeutic areas of interest to GSK.

18 Jun 2012

FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].

15 Jun 2012

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

15 Jun 2012

NCATS' Therapeutics Discovery program gains more industry collaborators

Five additional pharmaceutical companies have joined a National Institutes of Health-led effort to help scientists research promising new treatments for patients. Funding and molecular compound information is available now for the initial phase of the recently unveiled Discovering New Therapeutic Uses for Existing Molecules program.

13 Jun 2012